Shandong Lukang Pharmaceutical's (SHA:600789) vancomycin hydrochloride injection won a preliminary bid under China's drug procurement program, according to a Tuesday disclosure to the Shanghai bourse.
The drug is an antibiotic injection indicated for methicillin-resistant Staphylococcus aureus, among other bacteria, the company said in its filing.
Shandong Lukang's sales of the antibiotic reached 5.4 million yuan in 2025.